CorbinAlastair Pathios Therapeutics LimitedUnited Kingdom

Alastair is a Principal Scientist at Pathios Therapeutics, bringing over 10 years of experience in biomedical research & drug discovery across immuno-oncology and inflammatory disease, and holds a DPhil in Cellular and Molecular Medicine from the University of Oxford.

Wednesday, 18 June 2025

Time	Session

09:20 10:55	Symposium: New Drugs on the Horizon WestermarckJukka Co-Chair Finland CaffarelMaria M. Co-Chair Spain Drugging transcription factors: HSF1 and Brachyury WorkmanPaul Speaker United Kingdom Proffered Paper: Inhibition of WEE1 kinase activity to overcome secondary resistance to targeted therapies in colorectal cancer EACR25-0376 EACR25-0376 ArenaSabrina Presenter Italy Targeting chromatin proteins for therapeutic benefit in haematological malignancy SomervailleTim Speaker United Kingdom Proffered Paper: Reversing Acidic Immune Suppression in Cancer with PTT-4256, A First-In-Class Small Molecule Inhibitor of GPR65 EACR25-0553 EACR25-0553 CorbinAlastair Presenter United Kingdom PP2A inhibitor protein CIP2A is a prime target for TNBC therapy WestermarckJukka Speaker Finland Auditorium I

Time

Session

09:20

10:55

Symposium: New Drugs on the Horizon

WestermarckJukka Co-Chair Finland

CaffarelMaria M. Co-Chair Spain

Drugging transcription factors: HSF1 and Brachyury

WorkmanPaul Speaker United Kingdom
Proffered Paper: Inhibition of WEE1 kinase activity to overcome secondary resistance to targeted therapies in colorectal cancer

EACR25-0376

EACR25-0376

ArenaSabrina Presenter Italy
Targeting chromatin proteins for therapeutic benefit in haematological malignancy

SomervailleTim Speaker United Kingdom
Proffered Paper: Reversing Acidic Immune Suppression in Cancer with PTT-4256, A First-In-Class Small Molecule Inhibitor of GPR65

EACR25-0553

EACR25-0553

CorbinAlastair Presenter United Kingdom
PP2A inhibitor protein CIP2A is a prime target for TNBC therapy

WestermarckJukka Speaker Finland

Auditorium I